載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.4238
−US$0.0237 · -5.30%
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
收盤時
US$0.4238
−US$0.0237 · -5.30%
盤後
US$0.4234
−US$0.0004 · -0.09%
10月13日 下午6:33 ET
盤中時間採用ET。市場資料可能有所延遲。
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
日內區間
目前US$0.4238
52週區間
目前US$0.4238
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
55
合理估值
情緒
58
多空交錯
風險
66
高風險
動能
18
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
日內區間
目前US$0.4238
52週區間
目前US$0.4238
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | — | 1.51萬 USD |
| 銷貨成本 | — | — | — | 5094 USD | 1.73萬 USD |
| 毛利 | — | — | — | −5094 USD | −2213 USD |
| 研究與開發 | 798.11萬 USD | 719.85萬 USD | 810.08萬 USD | 266.54萬 USD | — |
| 銷售、一般及管理費用 | 1287.62萬 USD | 705.15萬 USD | 787.86萬 USD | 991.85萬 USD | 450.52萬 USD |
| 營業費用 | 2085.73萬 USD | 1425萬 USD | 1597.94萬 USD | 1258.39萬 USD | 450.52萬 USD |
| 利息收入 | 32.72萬 USD | 42.32萬 USD | 41.54萬 USD | — | — |
| 利息支出 | — | — | — | 102 USD | 508 USD |
| 折舊和攤銷 | 66.26萬 USD | 64.9萬 USD | 64.85萬 USD | 5094 USD | 1379 USD |
| 營業利益 | −2085.73萬 USD | −1425萬 USD | −1597.94萬 USD | −1258.9萬 USD | −450.74萬 USD |
| 淨利 | −2042.77萬 USD | −1390.46萬 USD | −1596.17萬 USD | −1393.65萬 USD | −217.35萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.00
上漲空間 607.88%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年1月2日 | 1:20 | — | — |
已生效 2024年1月2日
1:20
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
